Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1995 Aug;96(2):877–883. doi: 10.1172/JCI118134

Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes.

L M Faber 1, J van der Hoeven 1, E Goulmy 1, A L Hooftman-den Otter 1, S A van Luxemburg-Heijs 1, R Willemze 1, J H Falkenburg 1
PMCID: PMC185274  PMID: 7635982

Abstract

We investigated whether minor histocompatibility (mH) antigen-specific cytotoxic T lymphocytes (CTL) can discriminate between leukemic hematopoietic progenitor cells (leukemic-HPC) from AML or CML patients, the HPC from their remission bone marrow (remission-HPC), and normal HPC from their HLA-identical sibling bone marrow donor (donor-HPC). Specific lysis by CD8+ CTL clones was observed not only of the leukemic-HPC but also of the donor-HPC in 3/4 patient/donor combinations expressing mH antigen HA-1, 3/5 combinations expressing mH antigen HA-2, 2/3 combinations expressing mH antigen HA-3, and 2/2 combinations expressing mH antigen HY-A1. In four patient/donor combinations the recognition of the donor-HPC was clearly less than of the leukemic-HPC, indicating differential susceptibility to lysis by these mH CTL clones. In addition, differential recognition of leukemic-HPC and remission-HPC within seven patients was analyzed. In one patient expressing the HA-2 antigen on the leukemic cells the recognition of the remission-HPC was clearly less than of the leukemic-HPC. One CD4+ CTL clone showed specific lysis of the leukemic-HPC from an AML patient and a CML patient as well as of normal remission-HPC and donor-HPC. These results illustrate that in general CD8+ and CD4+ mH antigen specific CTL clones do not differentially recognize leukemic-HPC and normal-HPC. However, differences in susceptibility to lysis of malignant versus normal cells may contribute to a differential GVL effect.

Full text

PDF
878

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aizawa S., Sado T. Graft-versus-leukemia effect in MHC-compatible and -incompatible allogeneic bone marrow transplantation of radiation-induced, leukemia-bearing mice. Transplantation. 1991 Nov;52(5):885–889. doi: 10.1097/00007890-199111000-00025. [DOI] [PubMed] [Google Scholar]
  2. Apperley J. F., Mauro F. R., Goldman J. M., Gregory W., Arthur C. K., Hows J., Arcese W., Papa G., Mandelli F., Wardle D. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect. Br J Haematol. 1988 Jun;69(2):239–245. doi: 10.1111/j.1365-2141.1988.tb07628.x. [DOI] [PubMed] [Google Scholar]
  3. Barrett A. J., Horowitz M. M., Gale R. P., Biggs J. C., Camitta B. M., Dicke K. A., Gluckman E., Good R. A., Herzig R. H., Lee M. B. Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival. Blood. 1989 Aug 1;74(2):862–871. [PubMed] [Google Scholar]
  4. Busque L., Gilliland D. G. Clonal evolution in acute myeloid leukemia. Blood. 1993 Jul 15;82(2):337–342. [PubMed] [Google Scholar]
  5. Bär B. M., Schattenberg A., Mensink E. J., Geurts Van Kessel A., Smetsers T. F., Knops G. H., Linders E. H., De Witte T. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol. 1993 Mar;11(3):513–519. doi: 10.1200/JCO.1993.11.3.513. [DOI] [PubMed] [Google Scholar]
  6. Champlin R., Ho W., Gajewski J., Feig S., Burnison M., Holley G., Greenberg P., Lee K., Schmid I., Giorgi J. Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood. 1990 Jul 15;76(2):418–423. [PubMed] [Google Scholar]
  7. Deacock S., Schwarer A., Batchelor R., Goldman J., Lechler R. A rapid limiting dilution assay for measuring frequencies of alloreactive, interleukin-2-producing T cells in humans. J Immunol Methods. 1992 Feb 14;147(1):83–92. doi: 10.1016/s0022-1759(12)80032-9. [DOI] [PubMed] [Google Scholar]
  8. Faber L. M., van Luxemburg-Heijs S. A., Willemze R., Falkenburg J. H. Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med. 1992 Nov 1;176(5):1283–1289. doi: 10.1084/jem.176.5.1283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Falkenburg J. H., Goselink H. M., van der Harst D., van Luxemburg-Heijs S. A., Kooy-Winkelaar Y. M., Faber L. M., de Kroon J., Brand A., Fibbe W. E., Willemze R. Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Exp Med. 1991 Jul 1;174(1):27–33. doi: 10.1084/jem.174.1.27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fearon E. R., Burke P. J., Schiffer C. A., Zehnbauer B. A., Vogelstein B. Differentiation of leukemia cells to polymorphonuclear leukocytes in patients with acute nonlymphocytic leukemia. N Engl J Med. 1986 Jul 3;315(1):15–24. doi: 10.1056/NEJM198607033150103. [DOI] [PubMed] [Google Scholar]
  11. Fefer A., Sullivan K. M., Weiden P., Buckner C. D., Schoch G., Storb R., Thomas E. D. Graft versus leukemia effect in man: the relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation. Prog Clin Biol Res. 1987;244:401–408. [PubMed] [Google Scholar]
  12. Fialkow P. J., Singer J. W., Raskind W. H., Adamson J. W., Jacobson R. J., Bernstein I. D., Dow L. W., Najfeld V., Veith R. Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia. N Engl J Med. 1987 Aug 20;317(8):468–473. doi: 10.1056/NEJM198708203170802. [DOI] [PubMed] [Google Scholar]
  13. Frassoni F., Scarpati D., Bacigalupo A., Vitale V., Corvo R., Miceli S., Gualandi F., Occhini D., Clavio M., van Lint M. T. The effect of total body irradiation dose and chronic graft-versus-host disease on leukaemic relapse after allogeneic bone marrow transplantation. Br J Haematol. 1989 Oct;73(2):211–216. doi: 10.1111/j.1365-2141.1989.tb00254.x. [DOI] [PubMed] [Google Scholar]
  14. Frassoni F., Sessarego M., Bacigalupo A., Strada P., Repetto M., Miceli S., Occhini D., Defferrari R., Marmont A. Competition between recipient and donor cells after bone marrow transplantation for chronic myeloid leukaemia. Br J Haematol. 1988 Aug;69(4):471–475. doi: 10.1111/j.1365-2141.1988.tb02401.x. [DOI] [PubMed] [Google Scholar]
  15. Glass B., Uharek L., Gassmann W., Focks B., Bolouri H., Loeffler H., Mueller-Ruchholtz W. Graft-versus-leukemia activity after bone marrow transplantation does not require graft-versus-host disease. Ann Hematol. 1992 Jun;64(6):255–259. doi: 10.1007/BF01695466. [DOI] [PubMed] [Google Scholar]
  16. Goldman J. M., Gale R. P., Horowitz M. M., Biggs J. C., Champlin R. E., Gluckman E., Hoffmann R. G., Jacobsen S. J., Marmont A. M., McGlave P. B. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med. 1988 Jun;108(6):806–814. doi: 10.7326/0003-4819-108-6-806. [DOI] [PubMed] [Google Scholar]
  17. Goulmy E., Gratama J. W., Blokland E., Zwaan F. E., van Rood J. J. A minor transplantation antigen detected by MHC-restricted cytotoxic T lymphocytes during graft-versus-host disease. Nature. 1983 Mar 10;302(5904):159–161. doi: 10.1038/302159a0. [DOI] [PubMed] [Google Scholar]
  18. Goulmy E., Termijtelen A., Bradley B. A., van Rood J. J. Y-antigen killing by T cells of women is restricted by HLA. Nature. 1977 Apr 7;266(5602):544–545. doi: 10.1038/266544a0. [DOI] [PubMed] [Google Scholar]
  19. Horowitz M. M., Gale R. P., Sondel P. M., Goldman J. M., Kersey J., Kolb H. J., Rimm A. A., Ringdén O., Rozman C., Speck B. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990 Feb 1;75(3):555–562. [PubMed] [Google Scholar]
  20. Irschick E. U., Hladik F., Niederwieser D., Nussbaumer W., Holler E., Kaminski E., Huber C. Studies on the mechanism of tolerance or graft-versus-host disease in allogeneic bone marrow recipients at the level of cytotoxic T-cell precursor frequencies. Blood. 1992 Mar 15;79(6):1622–1628. [PubMed] [Google Scholar]
  21. Jones R. J., Ambinder R. F., Piantadosi S., Santos G. W. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood. 1991 Feb 1;77(3):649–653. [PubMed] [Google Scholar]
  22. Kaminski E., Hows J., Man S., Brookes P., Mackinnon S., Hughes T., Avakian O., Goldman J. M., Batchelor J. R. Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation. Transplantation. 1989 Oct;48(4):608–613. [PubMed] [Google Scholar]
  23. Kolb H. J., Mittermüller J., Clemm C., Holler E., Ledderose G., Brehm G., Heim M., Wilmanns W. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990 Dec 15;76(12):2462–2465. [PubMed] [Google Scholar]
  24. Marijt W. A., Veenhof W. F., Goulmy E., Willemze R., van Rood J. J., Falkenburg J. H. Minor histocompatibility antigens HA-1-, -2-, and -4-, and HY-specific cytotoxic T-cell clones inhibit human hematopoietic progenitor cell growth by a mechanism that is dependent on direct cell-cell contact. Blood. 1993 Dec 15;82(12):3778–3785. [PubMed] [Google Scholar]
  25. Marmont A. M., Horowitz M. M., Gale R. P., Sobocinski K., Ash R. C., van Bekkum D. W., Champlin R. E., Dicke K. A., Goldman J. M., Good R. A. T-cell depletion of HLA-identical transplants in leukemia. Blood. 1991 Oct 15;78(8):2120–2130. [PubMed] [Google Scholar]
  26. Nierle T., Bunjes D., Arnold R., Heimpel H., Theobald M. Quantitative assessment of posttransplant host-specific interleukin-2-secreting T-helper cell precursors in patients with and without acute graft-versus-host disease after allogeneic HLA-identical sibling bone marrow transplantation. Blood. 1993 Feb 1;81(3):841–848. [PubMed] [Google Scholar]
  27. OKunewick J. P., Kociban D. L., Machen L. L., Buffo M. J. The role of CD4 and CD8 T cells in the graft-versus-leukemia response in Rauscher murine leukemia. Bone Marrow Transplant. 1991 Dec;8(6):445–452. [PubMed] [Google Scholar]
  28. Perreault C., Décary F., Brochu S., Gyger M., Bélanger R., Roy D. Minor histocompatibility antigens. Blood. 1990 Oct 1;76(7):1269–1280. [PubMed] [Google Scholar]
  29. Porter D. L., Roth M. S., McGarigle C., Ferrara J. L., Antin J. H. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med. 1994 Jan 13;330(2):100–106. doi: 10.1056/NEJM199401133300204. [DOI] [PubMed] [Google Scholar]
  30. Schreiber K. L., Forman J. Effect of graft-versus-host disease on anti-tumor immunity. J Immunol. 1990 Mar 1;144(5):2018–2026. [PubMed] [Google Scholar]
  31. Sondel P. M., Hank J. A., Wendel T., Flynn B., Bozdech M. J. HLA identical leukemia cells and T cell growth factor activate cytotoxic T cell recognition of minor locus histocompatibility antigens in vitro. J Clin Invest. 1983 Jun;71(6):1779–1786. doi: 10.1172/JCI110933. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Sosman J. A., Oettel K. R., Smith S. D., Hank J. A., Fisch P., Sondel P. M. Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells. Blood. 1990 May 15;75(10):2005–2016. [PubMed] [Google Scholar]
  33. Theobald M., Bunjes D. Pretransplant detection of human minor histocompatibility antigen-specific naive and memory interleukin-2-secreting T cells within class I major histocompatibility complex (MHC)-restricted CD8+ and class II MHC-restricted CD4+ T-cell subsets. Blood. 1993 Jul 1;82(1):298–306. [PubMed] [Google Scholar]
  34. Theobald M., Nierle T., Bunjes D., Arnold R., Heimpel H. Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. N Engl J Med. 1992 Dec 3;327(23):1613–1617. doi: 10.1056/NEJM199212033272301. [DOI] [PubMed] [Google Scholar]
  35. Truitt R. L., Atasoylu A. A. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplant. 1991 Jul;8(1):51–58. [PubMed] [Google Scholar]
  36. Voogt P. J., Fibbe W. E., Marijt W. A., Goulmy E., Veenhof W. F., Hamilton M., Brand A., Zwann F. E., Willemze R., van Rood J. J. Rejection of bone-marrow graft by recipient-derived cytotoxic T lymphocytes against minor histocompatibility antigens. Lancet. 1990 Jan 20;335(8682):131–134. doi: 10.1016/0140-6736(90)90003-n. [DOI] [PubMed] [Google Scholar]
  37. Voogt P. J., Fibbe W. E., Veenhof W. F., Brand A., Goulmy E., van Rood J. J., Falkenburg J. H. Cell-mediated lysis of human hematopoietic progenitor cells. Leukemia. 1987 May;1(5):427–431. [PubMed] [Google Scholar]
  38. Voogt P. J., Goulmy E., Fibbe W. E., Veenhof W. F., Brand A., Falkenburg J. H. Minor histocompatibility antigen H-Y is expressed on human hematopoietic progenitor cells. J Clin Invest. 1988 Sep;82(3):906–912. doi: 10.1172/JCI113697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Voogt P. J., Goulmy E., Veenhof W. F., Hamilton M., Fibbe W. E., Van Rood J. J., Falkenburg J. H. Cellularly defined minor histocompatibility antigens are differentially expressed on human hematopoietic progenitor cells. J Exp Med. 1988 Dec 1;168(6):2337–2347. doi: 10.1084/jem.168.6.2337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Wagner J. E., Zahurak M., Piantadosi S., Geller R. B., Vogelsang G. B., Wingard J. R., Saral R., Griffin C., Shah N., Zehnbauer B. A. Bone marrow transplantation of chronic myelogenous leukemia in chronic phase: evaluation of risks and benefits. J Clin Oncol. 1992 May;10(5):779–789. doi: 10.1200/JCO.1992.10.5.779. [DOI] [PubMed] [Google Scholar]
  41. Weiden P. L., Flournoy N., Thomas E. D., Prentice R., Fefer A., Buckner C. D., Storb R. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979 May 10;300(19):1068–1073. doi: 10.1056/NEJM197905103001902. [DOI] [PubMed] [Google Scholar]
  42. Weiden P. L., Sullivan K. M., Flournoy N., Storb R., Thomas E. D. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med. 1981 Jun 18;304(25):1529–1533. doi: 10.1056/NEJM198106183042507. [DOI] [PubMed] [Google Scholar]
  43. de Bueger M., Bakker A., Van Rood J. J., Van der Woude F., Goulmy E. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol. 1992 Sep 1;149(5):1788–1794. [PubMed] [Google Scholar]
  44. van Els C. A., D'Amaro J., Pool J., Blokland E., Bakker A., van Elsen P. J., van Rood J. J., Goulmy E. Immunogenetics of human minor histocompatibility antigens: their polymorphism and immunodominance. Immunogenetics. 1992;35(3):161–165. doi: 10.1007/BF00185109. [DOI] [PubMed] [Google Scholar]
  45. van der Harst D., Goulmy E., Falkenburg J. H., Kooij-Winkelaar Y. M., van Luxemburg-Heijs S. A., Goselink H. M., Brand A. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. Blood. 1994 Feb 15;83(4):1060–1066. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES